Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ligand Pharmaceuticals, Inc shares valued at $255,036 were purchased by Sabba Stephen L on Mar 18 ’25. At $106.00 per share, Sabba Stephen L acquired 2,406 shares.
Also, Espinoza Octavio sold 5,000 shares, netting a total of over 575,148 in proceeds. Following the sale of shares at $115.03 each, the insider now holds 18,879 shares.
Before that, Espinoza Octavio had added 5,000 shares to its account. In a trade valued at $575,149, the Officer bought Ligand Pharmaceuticals, Inc shares for $115.03 each.
As published in their initiating research note from Stifel on April 10, 2025, Ligand Pharmaceuticals, Inc [LGND] has been a Buy and the price target has been revised to $143. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early October. As of July 30, 2024, RBC Capital Mkts has initiated its “an Outperform” rating for LGND.
Analyzing LGND Stock Performance
During the last five days, there has been a surge of approximately 3.63%. Over the course of the year, Ligand Pharmaceuticals, Inc shares have dropped approximately -2.03%. Shares of the company reached a 52-week high of $125.17 on 03/03/25 and a 52-week low of $93.58 on 04/09/25. A 50-day SMA is recorded $110.51, while a 200-day SMA reached $108.61.
Support And Resistance Levels for Ligand Pharmaceuticals, Inc (LGND)
According to the 24-hour chart, there is a support level at 102.14, which, if violated, would cause prices to drop to 99.31. In the upper region, resistance lies at 106.90. The next price resistance is at 108.83. RSI (Relative Strength Index) is 47.85 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.90, which suggests the price will increase in the coming days. Percent R is at 25.02%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Ligand Pharmaceuticals, Inc (LGND)?
On February 04, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $310.
